Management of patients with essential thrombocythemia: Current concepts and perspectives

Pathologie Biologie

Volumn 49, Issue 2, 2001, Pages 178-183

  Briere, J ^a   Guilmin, F ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Anagrelide; Bone marrow biopsy; Clonality; Essential thrombocythemia; Risk stratification

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANAGRELIDE; BUSULFAN; INTERFERON; MELPHALAN;

BLEEDING; BONE MARROW BIOPSY; CONFERENCE PAPER; EMBOLISM; HIGH RISK PATIENT; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDER; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS;

EID: 0035087103     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(00)00026-2     Document Type: Conference Paper

References (32)

1. Clonality analysis of haematopoiesis in essential thrombocythemia: Advantages of studying T-lymphocytes and platelets
2. A large proportion of patients with a diagnosis of essential thrombocythaemia do not have a clonal disorder and may be at lower risk of thrombotic complications
3. Is clonality status of young females with essential thrombocythaemia (ET) a reliable parameter for indication of cytoreductive treatment?
4. Epidemiology of the myeloproliferative disorders: Essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis
5. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
6. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies
7. Clinicopathology and histochemistry on bone marrow biopsies in chronic myeloproliferative disorders-a clue to diagnosis and classification
8. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis
9. Primary thrombocytaemia: Diagnostic criteria and a simple scoring system for positive diagnosis
10. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the thrombocythemia vera study group
11. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia
12. Erythromelalgia: A pathognomonic microvascular thrombotic complication in essential Thrombocythemia and Polycythemia Vera
13. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: Relationship with platelet count
14. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma
15. Life expectancy of patients with chronic non leukemic myeloproliferative disorders
16. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centres
17. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
18. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis
19. Leukemogenic risk of Hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis
20. Cytogenetic abnormalities and leukemic transformation in hydroxyurea treated patients with Philadelphia chromosome negative chronic myeloproliferative disease
21. Acute leukaemia after Hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications
22. Acute myeloid leukemia and myelodysplasticsyndromes following essential thrombocythemia treated with Hydroxyurea: High proportion of cases with 17p deletion
23. Essential Thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature
24. Treatment and clinical course of essential thrombocythaemia (ET): Preliminary results of a prospective multicenter trial
25. Anagrelide a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications
26. Aspirin as an antiplatelet drug
27. Primary thrombocythaemia: Diagnosis and management
28. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
29. Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin
30. Low dose aspirin in polycythaemia vera: A pilot study
31. No treatment for low risk thrombocythaemia: Results from a prospective study
32. Pregnancy in essential thrombocythaemia: Treatment and outcome in 19 cases